Rockefeller Capital Management L.P. Boosts Position in Illumina, Inc. (NASDAQ:ILMN)

Rockefeller Capital Management L.P. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,220 shares of the life sciences company’s stock after purchasing an additional 10,568 shares during the period. Rockefeller Capital Management L.P. owned 0.12% of Illumina worth $24,751,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ILMN. Bank of Stockton lifted its holdings in Illumina by 3.8% in the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after acquiring an additional 80 shares during the last quarter. Stephens Inc. AR increased its position in shares of Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after purchasing an additional 90 shares during the last quarter. Spire Wealth Management lifted its position in Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after buying an additional 97 shares during the last quarter. IFP Advisors Inc increased its position in shares of Illumina by 19.1% during the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after acquiring an additional 99 shares during the last quarter. Finally, Brooklyn Investment Group lifted its holdings in shares of Illumina by 20.5% in the 4th quarter. Brooklyn Investment Group now owns 611 shares of the life sciences company’s stock worth $82,000 after acquiring an additional 104 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ILMN has been the topic of a number of research reports. Royal Bank of Canada decreased their price target on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 8th. Canaccord Genuity Group cut their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, March 11th. Citigroup dropped their price objective on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a report on Monday, April 7th. Guggenheim cut their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and decreased their target price for the company from $177.00 to $140.00 in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $138.70.

Illumina Stock Performance

NASDAQ ILMN opened at $74.78 on Monday. The business’s 50-day moving average price is $88.58 and its 200 day moving average price is $122.25. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market cap of $11.85 billion, a P/E ratio of -9.74, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.